L-Carnitin Fresenius

Levocarnitine, the active ingredient in L-Carnitin Fresenius, is a nutrition supplement presented as an injectable solution for intravenous use. It is employed to correct carnitine deficiency and to support metabolic processes that rely on fatty‑acid oxidation, particularly in patients with renal impairment or inherited metabolic disorders. It is indicated for patients with primary or secondary carnitine deficiency and for those requiring metabolic support during dialysis or peri‑operative care.

GNH USA supplies L-Carnitin Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide, ensuring reliable delivery and regulatory compliance.

Levocarnitine is used to address disorders of carnitine metabolism and related energy‑deficiency states. - Primary carnitine deficiency: restores intracellular carnitine levels, enabling normal transport of long‑chain fatty acids into mitochondria for energy production. - Secondary carnitine deficiency (e.g., dialysis patients): replenishes carnitine lost during renal replacement therapy, improving muscle function and reducing fatigue. - Fatty‑acid oxidation disorders: provides the essential cofactor required for mitochondrial β‑oxidation, helping to prevent hypoglycaemia and metabolic crises. - Peri‑operative metabolic support: administered to patients undergoing major surgery to maintain energy metabolism and reduce postoperative complications.

Levocarnitine administered intravenously may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate nausea may occur during or shortly after infusion. - Vomiting: occasional vomiting can accompany gastrointestinal upset. - Headache: transient headache is reported in some patients. - Injection site reactions: erythema, pain or swelling at the infusion site.

Serious or Rare Side Effects: - Anaphylaxis: rare but severe hypersensitivity reaction requiring immediate medical intervention. - Cardiac arrhythmia: occasional reports of rhythm disturbances, especially in patients with underlying heart disease. - Metabolic acidosis: very rare occurrence of acid‑base imbalance necessitating monitoring.

When using L‑Carnitin Fresenius, several precautionary measures should be observed to ensure patient safety and product integrity. - Renal impairment: adjust dose and monitor plasma carnitine levels in patients with reduced kidney function. - Pregnancy and lactation: use only if potential benefits outweigh risks, after careful clinical assessment. - Concomitant anticoagulants: monitor coagulation parameters as levocarnitine may potentiate anticoagulant effects. - Infusion rate: administer slowly to minimize hypotension and related cardiovascular events. - Hypersensitivity: discontinue infusion immediately if signs of allergic reaction such as rash, itching, or respiratory distress appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levocarnitine can interact with certain medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Valproic acid: may increase risk of hyperammonemia when combined with levocarnitine. - Warfarin: levocarnitine can potentiate anticoagulant effect, increasing bleeding risk. - Antibiotics affecting renal function (e.g., aminoglycosides): may exacerbate carnitine loss.

Moderate Interactions (Monitor Closely): - Insulin: levocarnitine may influence glucose metabolism; monitor blood sugar levels. - Thyroid hormone therapy: may alter carnitine turnover; assess thyroid function periodically. - Statins: combined use may increase risk of muscle toxicity; observe for myalgia or weakness.